Published • loading... • Updated
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
Summary by Charleston Gazette-Mail
33 Articles
33 Articles
keenesentinel.com+32 Reposted by 32 other sources
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
SHANGHAI and HONG KONG, June 9, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies…
Coverage Details
Total News Sources33
Leaning Left8Leaning Right4Center7Last UpdatedBias Distribution42% Left
Bias Distribution
- 42% of the sources lean Left
42% Left
L 42%
C 37%
R 21%
Factuality
To view factuality data please Upgrade to Premium
